

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS V LLC;
HAYMAN CREDES MASTER FUND, L.P.;
HAYMAN ORANGE FUND SPC – PORTFOLIO A;
HAYMAN CAPITAL MASTER FUND, L.P.;
HAYMAN CAPITAL MANAGEMENT, L.P.;
HAYMAN OFFSHORE MANAGEMENT, INC.;
HAYMAN INVESTMENTS, LLC;
NXN PARTNERS, LLC;
IP NAVIGATION GROUP, LLC;
J KYLE BASS, and ERICH SPANGENBERG,
Petitioner,

v.

BIOGEN MA INC.,
Patent Owner.

Case: IPR2015-01993
U.S. Patent No. 8,399,514

BIOGEN'S EXHIBIT LIST AS OF OCTOBER 21, 2016

Exhibit	Description
Exhibit 2001	Hayman Capital Management, L.P. Form ADV Part 2A Brochure, June 1, 2015
Exhibit 2002	First Amended Petition in IPR2015-01136 (Paper No. 9)
Exhibit 2003	Biogen's Preliminary Response in IPR2015-01136 (Paper No. 21)
Exhibit 2004	Declaration of Dr. Linberg in IPR2015-01136 (Exhibit 1005A)
Exhibit 2005	Ludwig Kappos et al., "A Randomized, Placebo-Controlled Phase 2 Trial of a Novel Oral Fumarate, BG00012, in Patients With Relapsing-Remitting Multiple Sclerosis," from the 15 th meeting of the European Neurological Society, Vienna Austria (June 18-22, 2005) (presented on June 20, 2005)
Exhibit 2006	Final Program for Fifteenth Meeting of the European Neurological Society, June 18-22, 2005, Vienna Austria (http://www.congrex.ch/2005/ens2005/)
Exhibit 2007	Scientific Program from Fifteenth Meeting of the European Neurological Society, June 18-22, 2005 (http://registration.akm.ch/einsicht.php?XNKONGRESS_ID=18&XNSPRACHE_ID=2)
Exhibit 2008	Program from Wednesday, June 22, 2005 from Fifteenth Meeting of the European Neurological Society (http://registration.akm.ch/einsicht.php?XNKONGRESS_ID=18&XNSPRACHE_ID=2&XNMASKEN_ID=200&XS DATUM=2005-06-20)
Exhibit 2009	Final Office Action dated October 12, 2012, in U.S. Patent Application No. 13/372,426
Exhibit 2010	Reply to Final Office Action filed December 12, 2012, in U.S. Patent Application No. 13/372,426
Exhibit 2011	Declaration of Richard A. Rudick, M.D. Under 37 C.F.R. § 1.132 filed on August 3, 2012 in U.S. Patent Application No.

Exhibit	Description
	13/372,426
Exhibit 2012	Notice of Allowance and Fees Due dated December 26, 2012 in U.S. Patent Application No. 13/372,426
Exhibit 2013	Poster Session 5, Multiple Sclerosis, Wednesday, June 22, 2005 from Fifteenth Meeting of the European Neurological Society (http://registration.akm.ch/einsicht.php?XNMASKEN_ID=300&XNKONGRESS_ID=18&XNSPRACHE_ID=2&XNSESSION_ID=748)
Exhibit 2014	Declaration of Gilmore O'Neill, M.D.
Exhibit 2015	Declaration of Richard Brudnick
Exhibit 2016	Redacted License Agreement between Fumapharm AG and Biogen, Inc. dated September 25, 2003
Exhibit 2016A	License Agreement between Fumapharm AG and Biogen, Inc. dated September 25, 2003 (PROTECTIVE ORDER MATERIAL)
Exhibit 2017	Redacted Stock Purchase Agreement dated May 26, 2006
Exhibit 2017A	Stock Purchase Agreement dated May 26, 2006 (PROTECTIVE ORDER MATERIAL)
Exhibit 2018	SEC'Y OF THE COMMW. OF MASS., CORPS. DIV., BUSINESS ENTITY SUMMARY FOR BIOGEN MA INC. dated May 25, 2016
Exhibit 2019	<i>Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis</i> , BUSINESS WIRE (May 31, 2006, 7:00 AM EDT), http://www.businesswire.com/news/home/20060531005276/en/Biogen-Idec-Acquire-Fumapharm-AG-Consolidates-Ownership
Exhibit 2020	Biogen Idec Inc., Quarterly Report (Form 10-Q) (Nov. 9,

Exhibit	Description
	2006)
Exhibit 2021	Certified copy of Patent Assignment, Reel/Frame 018556-0294 (Executed Dec. 20, 2000)
Exhibit 2022	Certified copy of Patent Assignment, Reel/Frame 018556-0364 (Executed June 24, 2003)
Exhibit 2023	Curriculum Vitae of Richard Brudnick
Exhibit 2024	Petition in IPR2015-01993 (Paper No. 1)
Exhibit 2025	Ralf Gold et al., <i>Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis</i> , 367 N. ENGL. J. MED. 1098 (2012)
Exhibit 2026	Robert J. Fox et al., <i>Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis</i> , 367 N. ENGL. J. MED. 1087 (2012)
Exhibit 2027	Hillel S. Panitch et al., <i>Randomized, Controlled Trial of Dextromethorphan/Quinidine for Pseudobulbar Affect in Multiple Sclerosis</i> , 59 ANNALS OF NEUROL. 780 (2006)
Exhibit 2028	Erik P. Piro et al., <i>Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect</i> , 68 ANNALS OF NEUROL. 693 (2010)
Exhibit 2029	Employee's Proprietary Information and Inventions Agreement between Gilmore O'Neill and Biogen, Inc. (executed Apr. 28, 2003)
Exhibit 2030	Employee Proprietary Information and Inventions and Dispute Resolution Agreement between Gilmore O'Neill and Biogen Idec Inc. (executed Mar. 29, 2004)
Exhibit 2031	<i>Biogen Idec Announces Positive Top Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis</i> , BIOGEN MEDIA (Apr. 11, 2011, 7:00 AM EDT), http://media.biogen.com/press-

Exhibit	Description
	release/multiple-sclerosis-ms/biogen-idec-announces-positive-top-line-results-first-phase-3-tr
Exhibit 2032	Employee Proprietary Information and Inventions and Dispute Resolution Agreement between Matvey Lukashev and Biogen Idec Inc. (executed Apr. 13, 2004)
Exhibit 2033	Daily Dosing Date Ranges Chart
Exhibit 2034	SEC'Y OF THE COMMW. OF MASS., CORPS. DIV., BUSINESS ENTITY SUMMARY FOR BIOGEN INC. dated May 25, 2016
Exhibit 2035	Rui Wang et al., <i>Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials</i> , 357 N. ENGL. J. MED. 2189 (2007)
Exhibit 2036	Peter M. Rothwell, <i>Subgroup Analysis in Randomised Controlled Trials: Importance, Indications, and Interpretation</i> , 365 LANCET 176 (2005)
Exhibit 2037	Andrew D. Oxman et al., <i>A Consumer's Guide to Subgroup Analyses</i> , 116 ANNALS OF INTERNAL MED. 78 (1992)
Exhibit 2038	Declaration of Ronald A. Thisted, Ph.D.
Exhibit 2039	Curriculum Vitae of Ronald A. Thisted, Ph.D.
Exhibit 2040	Declaration of Jose Miranda, Ph.D.
Exhibit 2041	Curriculum Vitae of Jose Miranda, Ph.D.
Exhibit 2042	Declaration of Richard C. Brundage, Pharm.D., Ph.D.
Exhibit 2043	Curriculum Vitae of Richard C. Brundage, Pharm.D., Ph.D.
Exhibit 2044	Declaration of Richard A. Rudick, M.D.
Exhibit 2045	Curriculum Vitae of Richard A. Rudick, M.D.
Exhibit 2046	Declaration of Daniel Wynn, M.D. FACNS FAASM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.